Skip to main content
. Author manuscript; available in PMC: 2019 Dec 6.
Published in final edited form as: Bioconjug Chem. 2019 Apr 15;30(5):1425–1433. doi: 10.1021/acs.bioconjchem.9b00161

Figure 4.

Figure 4.

CEST MRI detection of EDB-FN in KPC pancreatic tumors using Dex10-ZD2. (a) Schematic of the tumor position. (b) Immunohistofluorescence stains of EDB-FN in the tumors and muscle. Blue: nucleus, yellow: EDB-FN, scale bar: 50 μm. (c) Comparison of the CEST MRI images of two representative mice injected with Dex10 (left) and Dex10-ZD2, respectively. From the top to bottom: the T2-weighted (T2w) images showing the ROIs of tumors; CEST images before and post the injection, as quantified by the MTRasym maps at 1 ppm; and the overlaid contrast enhancement of the tumor regions, as quantified by the ΔMTRasym (1 ppm) maps at 45 min postinjection.